Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro- Core registry by Giannitsis, Evangelos et al.
1Giannitsis E, et al. BMJ Open 2019;9:e028311. doi:10.1136/bmjopen-2018-028311
Open access 
Multicentre cross-sectional 
observational registry to monitor the 
safety of early discharge after rule-out 
of acute myocardial infarction by 
copeptin and troponin: the Pro-
Core registry
Evangelos Giannitsis,1 Piers Clifford,2 Anna Slagman,3,4 Ralph Ruedelstein,5 
Christoph Liebetrau,6,7 Christian Hamm,6,7 Didier Honnart,8 Kurt Huber,9,10 
Jörn Ole Vollert,11 Carlo Simonelli,11 Malte Schröder,12 Jan C Wiemer,11 
Matthias Mueller-Hennessen,1 Hinrich Schroer,13 Kim Kastner,3 Martin Möckel  3,4
To cite: Giannitsis E, Clifford P, 
Slagman A, et al.  Multicentre 
cross-sectional observational 
registry to monitor the safety of 
early discharge after rule-out 
of acute myocardial infarction 
by copeptin and troponin: the 
Pro-Core registry. BMJ Open 
2019;9:e028311. doi:10.1136/
bmjopen-2018-028311
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
028311).
Received 1 December 2018
Revised 16 May 2019
Accepted 25 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Martin Möckel;  
 martin. moeckel@ charite. de
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Objectives There is sparse information on the safety of 
early primary discharge from the emergency department 
(ED) after rule-out of myocardial infarction in suspected 
acute coronary syndrome (ACS). This prospective registry 
aimed to confirm randomised study results in patients 
at low-to-intermediate risk, with a broader spectrum of 
symptoms, across different institutional standards and with 
a range of local troponin assays including high-sensitivity 
cTn (hs-cTn), cardiac troponin (cTn) and point-of-care 
troponin (POC Tn).
Design Prospective, multicentre European registry.
setting 18 emergency departments in nine European 
countries (Germany, Austria, Switzerland, France, Spain, 
UK, Turkey, Lithuania and Hungary)
Participants The final study cohort consisted of 2294 
patients (57.2% males, median age 57 years) with 
suspected ACS.
Interventions Using the new dual markers strategy, 1477 
patients were eligible for direct discharge, which was 
realised in 974 (42.5%) of patients.
Main outcome measures The primary endpoint was all-
cause mortality at 30 days.
results Compared with conventional workup after dual 
marker measurement, the median length of ED stay 
was 60 min shorter (228 min, 95% CI: 219 to 239 min 
vs 288 min, 95% CI: 279 to 300 min) in the primary 
dual marker strategy (DMS) discharge group. All-cause 
mortality was 0.1% (95% CI: 0% to 0.6%) in the primary 
DMS discharge group versus 1.1% (95% CI: 0.6% to 
1.8%) in the conventional workup group after dual marker 
measurement. Conventional workup instead of discharge 
despite negative DMS biomarkers was observed in 503 
patients (21.9%) and associated with higher prevalence of 
ACS (17.1% vs 0.9%, p<0.001), cardiac diagnoses (55.2% 
vs 23.5%, p<0.001) and risk factors (p<0.01), but with a 
similar all-cause mortality of 0.2% (95% CI: 0% to 1.1%) 
versus primary DMS discharge (p=0.64).
Conclusions Copeptin on top of cardiac troponin supports 
safe discharge in patients with chest pain or other 
symptoms suggestive of ACS under routine conditions 
with the use of a broad spectrum of local standard POC, 
conventional and high-sensitivity troponin assays. 
trial registration number NCT02490969.
IntrODuCtIOn
Chest pain accounts for approximately 
eight million annual emergency department 
(ED) visits in the USA,1 rendering chest 
pain the second most common presenting 
symptom. In a pooled analysis on 51 observa-
tional trials, the prevalence of the final diag-
nosis of acute coronary syndrome (ACS) was 
confirmed in a median of 14%, with a range 
from 5% to 42%.2
strengths and limitations of this study
 ► This is the first large European registry demonstrat-
ing the safety of the dual marker strategy using 
cardiac troponin and copeptin for early discharge in 
patients with suspected acute coronary syndrome.
 ► The study recruited less selected patients, a broad-
er range of local cardiac troponin (cTn) assays and 
assay generations and across different institutional 
standards than former studies and thus reflects daily 
routine in clinical practice.
 ► The study has been carried out in experienced cen-
tres, thus in settings with lower clinical expertise 
results may differ.
 ► The very low mortality rate does not allow any ex-
ploratory analyses on the safety of discharge by 
centre volumes, experience of physicians, local cTn 
assay or assay generation.
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An effective risk stratification is paramount to select 
the most appropriate decision for admission or direct 
discharge because admission of patients at low or very low 
risk is not safe3 4 as it increases the risk to receive unnec-
essary coronary angiography, coronary interventions, 
multiple re-admissions3 and eventually the risk of peripro-
cedural myocardial injury or type 4 myocardial infarction 
(MI), and procedure-related major bleedings.4 Moreover, 
unselected admission of chest pain patients for further 
workup for the evaluation of ACS is time consuming and 
costly.5 6 During an interval of only 9 years (from 1999 
to 2008), the use of advanced medical imaging for ED 
visits related to chest pain was found to increase dramat-
ically by 367.6% in the CDC/NCHS (Centers for Disease 
Control and Prevention/National Center for Health 
Statistics), National Hospital Ambulatory Medical Care 
Survey.7 On the other hand, early discharge is also not 
without risk, as up to 2% to 5% of patients with ACS are 
reported to be inappropriately discharged from the ED 
every year5 8 although the methodology to assess these 
numbers is limited (no complete follow-up of all patients, 
no exact differentiation between incident and prevalent 
acute myocardial infarction (AMI) and the components 
of ACS). Nevertheless, missed or incident AMI early after 
discharge is associated with a HR for death of 1.7% to 
1.9%.8 Missed AMIs account for 20% of USA emergency 
medicine related litigation dollars.9 Currently, use of 
high-sensitivity cardiac troponins (hs-cTn) has improved 
the accuracy and earlier detection of an MI,10–13 and 
very low concentrations of hs-cTn have been reported to 
safely rule-out an MI and to be associated with rates of 
death or MI below 1%.14–17 Accordingly, 2015 European 
Society of Cardiology (ESC) guidelines on acute coronary 
syndrome without ST-segment elevation (NSTE-ACS)10 
discourage routine coronary angiography in low risk 
patients and recommend early discharge after clinical 
risk stratification, and a pre-discharge or post-discharge 
stress imaging test for the decision of a selective inva-
sive strategy. Supporting evidence for early uneventful 
discharge of low risk patients stems mainly from observa-
tional studies14 15 18 19 where investigators were commonly 
blinded to the investigational hs-cTn results, were unaware 
of retrospectively derived optimal decision cut-offs, and 
managed patients at their own discretion following stan-
dards of care applicable at that time. In fact, most of the 
patients who retrospectively fulfilled early rule-out criteria 
were kept in hospital and neither medical measures nor 
non-cardiac diagnoses are reported. Only few interven-
tional clinical trials evaluated the safety of a randomised 
allocation to early discharge versus conventional care 
in patients at low20 21 or low-to-intermediate high risk.22 
The Biomarkers-in-Cardiology 8 (BIC-8) trial22 tested 
the utility of a dual biomarker strategy using normal 
cTn or hs-cTn values, that is below the upper limit of 
normal, mainly the 99th percentile, together with normal 
Copeptin values below the 95th percentile (<10 pmol/L) 
to identify candidates for direct early discharge from the 
ED. The findings demonstrated that this strategy reduced 
the length of observation time in the ED or chest pain 
unit and increased rates of discharge at a low risk for 
major adverse cardiovascular events that was comparable 
or even lower in the per protocol analysis to standard of 
care. Compared with serial troponin-based protocols, 
advantages of the dual marker strategy include the ability 
of instant rule-out of MI without the need for additional 
blood draw, high sensitivities and negative predictive 
values (NPVs) for AMI of Copeptin in combination with 
conventional or contemporary sensitive cTn assays,23–28 
or point-of-care troponin (POCT),29 particularly when 
hs-cTn or validated hs-cTn assays are not available, and 
supporting data for a safe discharge from a large, appro-
priately powered randomised multicentre trial.22 The 
value of Copeptin on top of detectable but still normal 
cTn or hs-cTn for rule-out of MI has been studied exten-
sively and the dual marker strategy (DMS) algorithm has 
been quoted as an additional option for instant rule-out 
in 2015 ESC guidelines.10 In contrast, there is sparse 
information from randomised trials on the safety of 
discharge20 21 and the safety of discharge using a prespec-
ified algorithm has rarely been investigated in a prospec-
tive registry.
Therefore, the aim of the present multicentre observa-
tional trial was to confirm the safety of this strategy that 
was previously reported in a randomised interventional 
trial22 in routine clinical practice, across a broad spectrum 
of cTn assays including POCT, in an unselected popula-
tion with a broader range of symptoms, and at low-to-in-
termediate risk presenting with suspected ACS to 18 EDs 
in Europe and Turkey.
MethODs
The Pro-Core is a multicentre, international observa-
tional trial with 18 participating centres (online supple-
mentary figure 1S) in Europe and formally Near East 
(Ankara, Turkey).
We enrolled adult men and women who present to an 
ED or chest pain unit (CPU) with signs and symptoms 
suggestive of NSTE-ACS. Eligible patients qualifying for 
the DMS strategy were recruited consecutively but entry 
was restricted to patients with a low or intermediate 
GRACE (Global Registry of Acute Coronary Events) score.
Patients were eligible if they were aged ≥18 years, 
presented with symptoms suggestive of ACS such as acute 
chest discomfort, angina pectoris or dyspnoea as leading 
symptoms. Patients presenting with ST-segment elevation 
or a final diagnosis of ST-segment elevation myocardial 
infarction (STEMI) were excluded from analysis (see 
figure 1 for patient flow).
Patients underwent clinical assessment that included 
medical history, physical examination, standard blood test 
including measurements of local (hs)-cTn, Copeptin and 
12-lead ECG. Baseline information included the Killip 
class, and clinical information to calculate the GRACE 
score. Other clinical scores were not tested prospectively 
prohibiting any conclusion on their clinical usefulness. 
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Physicians had access to all clinical information including 
Copeptin and cTn results that were reported with local 
turn-around-times. Decision for primary discharge after 
rule-out using the dual biomarker strategy, or for disposi-
tion of patients if MI was not ruled out was left at the discre-
tion of the attending physician. Patients were excluded if 
high risk features were evident (eg, the GRACE score was 
above 140) and if hospital admission was obviously neces-
sary at presentation for any reason. Final diagnosis of 
NSTE-ACS was performed by the ED physician applying 
the criteria of the third universal definition of AMI.30 
Unstable angina was diagnosed in the presence of new or 
worsening symptoms of suspected myocardial ischaemia 
but either normal or undetectable cTn concentrations 
in serial blood draws, or a cTn together with a Copeptin 
below the decision limit at presentation. Importantly, clas-
sification of ACS was done by the treating physician and 
was not subject of retrospective adjudication. All patients 
were contacted at 30 days to assess all-cause mortality. 
Number of patients was limited to 300 patients per partic-
ipating site to limit centre bias.
biomarkers and rule-out algorithms
Copeptin and cardiac troponin were tested from fresh 
unfrozen blood from a single blood sample drawn at 
admission to the ED or CPU as part of the routine patient 
management.
Copeptin was measured using the automated fluoro-im-
munoassay B∙R∙A∙H∙M∙S Copeptin proAVP KRYPTOR 
for the quantitative measurement of C-terminal pro-ar-
ginine-vasopressin (CT-proAVP, Copeptin) in human 
serum and plasma on the B∙R∙A∙H∙M∙S KRYPTOR 
compact PLUS platform. The test has a detection limit of 
0.69 pmol/L and a functional assay sensitivity (detected 
by inter-assay precision of 20% CV) of 1.08 pmol/L.
The recommended cut-off for the decision between a 
positive and a normal test is 10 pmol/L, corresponding 
to the 95th percentile of a healthy reference population. 
This cut-off was used in the randomised controlled trial 
by Möckel et al,22 and is the recommended cut-off for the 
rule-out algorithms for MI.
Cardiac troponin was measured at the individual insti-
tutions according to standard practice. An overview on 
local assays and cut-offs is provided as online supplemen-
tary table 1S). Briefly, Roche Elecsys hs-cTnT was used 
in 39%, followed by Abbott Architect hs-cTnI, Siemens 
(Vista, Loci), Beckman Access TnI, and Radiometer 
(third generation cTnT) in 22%, 22%, 11% and 6%, 
respectively. Conventional and high-sensitivity assays were 
permitted for the early rule-out strategy.
A patient qualified as rule-out and for early discharge 
if he presented with signs and symptoms suggestive of 
ACS, together with a low-to-intermediate risk profile 
defined as the absence of high risk features (eg, a GRACE 
score <140), and a combined negative testing of Copeptin 
and troponin, defined as Copeptin below 10 pmol/L and 
cardiac troponin below the local AMI decision limit as 
recommended by the guidelines, mostly the 99th percen-
tile value of a healthy reference population provided by 
the manufacturer.
Follow-up and clinical endpoints
The primary objective was to evaluate 30 day all-cause 
mortality in patients in whom acute myocardial infarc-
tion was ruled-out using the early dual marker rule-out 
strategy and who are therefore directly discharged from 
the ED. All-cause mortality was preferred over cardiovas-
cular death because collection of information is more 
convenient and because the majority of eligible patients 
presented to the EDs with non-coronary and non-cardiac 
diagnoses.
The secondary objectives were evaluated in all patients, 
irrespective of biomarker test results and disposition. 
Secondary endpoints included the diagnosis of acute 
myocardial infarction, final hospital diagnoses, time to 
discharge/transfer from the ED/CPU, disposition deci-
sion (discharge or admission), length of hospital stay, 
intensive care unit-treatment, performance of coro-
nary angiography/percutaneous coronary intervention 
(PCI)/coronary artery bypass grafting (CABG), perfor-
mance of ECGs, stress testing, imaging, performance of 
cardiovascular monitoring, in-hospital all-cause mortality, 
30 day all-cause mortality.
The study protocol also addressed patients where 
the protocol was violated, that is, those who were not 
primarily discharged or not admitted although criteria 
were fulfilled (over-rule). The reasons for over-rule or 
other protocol violations were registered.
The study complies with the Declaration of Helsinki. 
The positive vote was sent to all study sites. The principle 
investigator decided based on local and national rules, 
whether a separate local ethics committee submission was 
necessary. Additional ethics approvals were obtained from 
the sites listed in the online supplementary table 2S. The 
ethics committee approved that anonymised routine data 
of patients were used without informed consent for this 
registry. The study was registered before enrollment of the 
first patient.
Figure 1 Patient flow chart. ACS, acute coronary syndrome. 
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statistical evaluation
Enrolment was restricted to a maximum number of 300 
patients per centre to ensure generality by avoiding the 
dominance of single centres. The total number of patients 
enrolled therefore depended rather on the number of 
participating centres than on their enrolment performance. 
As the primary objective of this registry was the monitoring 
of an already routinely applied clinical algorithm, no 
confirmatory study design was chosen and there was no 
sample size calculation performed. An exploratory analysis 
of the safety of DMS by local cTn assay or assay generation, 
or by study centre was not done as there was only one death 
precluding meaningful analysis. All data were entered into 
an online electronic case report form. Group comparisons 
for categorical variables were performed using X2 tests and 
for numerical variables using Wilcoxon rank-sum tests. A 
p value below 0.05 was considered significant (no correc-
tion for multiple testing conducted) and 95% CIs were 
determined for binary all-cause death at 30 days by the 
method of Clopper and Pearson and for numeric length of 
stay in the ED/CPU by 2.5%-quantiles and 97.5%-quantiles 
estimated by bootstrapping.
Statistical analyses were performed using the software R 
V.3.1.2 and SPSS (IBM SPSS Statistics, V.21).
Patient and public involvement
Patients or public were not involved in the development 
of the study protocol.
results
A total of 2401 consecutive patients with suspected ACS 
were screened from 16 September 2015 until the end of 
recruitment on 23 May 2017. Of these, 107 patients were 
excluded from analysis due to incomplete biomarker or 
clinical information, withdraw of informed consent or 
double entry (see patient flow diagram; figure 1). The 
final study cohort consisted of 2294 patients (57.2% males, 
median age 57 years) with suspected ACS. Numbers of 
recruited patients varied by study site but were limited 
per protocol to a maximum of 300 enrolments per site. 
The exact numbers of recruited patients are displayed in 
online supplementary figure 1S.
The most prevalent leading symptom at presentation 
(online supplementary figure 2S, table 1) was chest pain 
in 70.6% (n=1619), followed by diffuse or initially mixed 
symptoms in 12.9% (n=297), dyspnoea in 5.2% (n=119), 
abdominal pain in 2.9% (n=66), focal neurology in 0.7% 
(n=16), headache in 0.4% (n=9) or none of the listed 
symptoms in 7.3% (n=168). As expected from the inclu-
sion criteria, the study cohort represented a low-to-inter-
mediate risk group with a median GRACE score of 89 
(IQR: 67 to 114) and a Killip class of 1 in 96% of cases 
(n=2084). Time from onset of symptoms to presentation 
was below 12 hours in 50.8%. An interval of 0 to 3 hours, 
3 to 6 hours and 6 to 12 hours was registered in 26.3% 
(n=558), 13.3% (n=283) and 11.2% (n=238) of patients, 
respectively. ECG at presentation was non-diagnostic in 
87.3% of patients. Regarding initial cTn and Copeptin 
results, a total of 2017 patients (87.9%) were below the 
diagnostic cut-off of the local cTn, and 1615 patients 
(70.4%) below the cut-off for Copeptin. A total of 1477 
patients (64.4%) were below the decision cut-off for 
both biomarkers fulfilling the criteria for early primary 
discharge from the ED (theoretically maximal efficiency).
Clinical pathways
Nine hundred and seventy-four patients (42.5%) were 
categorised into the primary discharge after fast rule-out 
pathway, and 1320 patients into the conventional workup 
pathway. Of these, 654 patients did not follow a predefined 
pathway but were either admitted although qualified for 
primary discharge (n=503, 21.9%), or were discharged 
although not ruled out (n=151, 6.6%), see figure 2.
In the entire cohort, the overall rate of an ACS diag-
nosis was 12.7% (n=288), non-cardiac chest pain 28.8%, 
rhythm disorders 8.7%, pulmonary disorders 6.8%, stable 
CAD 6.8%, hypertensive crisis 6.3% and gastrointestinal 
disease 5.5%. Other cardiac diagnoses were present in 
4%, and other unspecified diagnoses in 16.3% of cases 
(online supplementary figure 3S).
In the conventional care pathway, an ACS was diag-
nosed in 21.1% (n=279) with the majority classified as a 
NSTE-ACS (n=172, 61.6%). STEMI was an exceptional 
diagnosis in 15 patients (5.2%) since patients with STEMI 
were routed directly to the catheterisation laboratory in 
most institutions and were not intended for inclusion. 
Only if STEMI was diagnosed later and not at admission 
such patients were enrolled. Other diagnoses included 
non-cardiac chest pain in 18.8% (n=247), rhythm disor-
ders in 5.9% (n=133), stable CAD in 8.9% (n=117), 
pulmonary disease in 6.8% (n=90), hypertensive crisis in 
5.9% (n=77), gastrointestinal disease in 4.7% (n=62) and 
other diagnoses in 14.1% (n=185).
In the primary discharge after fast rule-out pathway, only 
nine patients (0.9%) were diagnosed as having an ACS, 
mostly unstable angina (n=4) or unclassified ACS (n=4), 
with only one case (0.1%) diagnosed as non-ST-segment 
elevation myocardial infarction (NSTEMI) (NPV for MI 
of 99.9%). Rate of admission was only 0.1% due to a case 
where admission was forced by the referring primary care 
physician although discharge was planned.
There were two different ways how local investiga-
tors over-ruled the intended pathway. The larger group 
consisted of 503 patients (21.9%) who were allocated to 
the conventional care pathway at the discretion of the 
local investigator although they were categorised into 
the primary discharge after fast rule-out pathway. The 
second group consisted of 151 patients (6.6%) who were 
primarily discharged although they should have received 
conventional care. Reasons for the over-rule consisted 
mainly of decisions of the physician to admit to hospital 
based on clinical judgement. Minor reasons were opposi-
tion of patients against serial blood sampling (n=2) and 
other unspecified reasons (n=6).
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There were differences between the primary discharge 
after fast rule-out pathway and the over-rulers into the 
conventional care pathway (table 2). Patients were older, 
more frequently males, had more often a history of CAD 
or previous MI, more risk factors including a higher 
prevalence of arterial hypertension, hypercholestero-
laemia and diabetes mellitus. In addition, patients had 
more often a diagnostic ECG, and higher GRACE scores. 
In addition, these patients received more often an ACS 
diagnosis, that is, a diagnosis of unstable angina, and 
Table 1 Baseline characteristics of the patients
Variable Category total (n=2294)
primary discharge 
after fast rule out 
(n=974)
conventional 
work up (n=1320) P value
Age 59 (46, 72) 51 (39, 62) 65 (52, 75.25) <0.001
Gender Female 42.8% (981) 49.7% (484) 37.7% (497) <0.001
Onset of symptoms 
before presentation
0–3 hour 26.3% (558) 26% (228) 26.5% (330) 0.053
3–6 hour 13.3% (283) 11.8% (103) 14.4% (180)
6–12 hour 11.2% (238) 13.1% (115) 9.9% (123)
>12 hour 49.2% (1043) 49.1% (430) 49.2% (613)
Leading symptom Chest pain 70.6% (1619) 76.9% (749) 65.9% (870) <0.001
Diffuse symptoms/
initially mixed symptoms
12.9% (297) 9.9% (96) 15.2% (201)
None of the previous 7.3% (168) 6.6% (64) 7.9% (104)
Dyspnoea 5.2% (119) 2.5% (24) 7.2% (95)
Abdominal pain 2.9% (66) 3.1% (30) 2.7% (36
Focal neurology 0.7% (16) 0.4% (4) 0.9% (12)
Headache 0.4% (9) 0.7% (7) 0.2% (2)
History of CAD 29.2% (656) 16.8% (158) 38.2% (498) <0.001
History of MI 11.7% (262) 7.3% (69) 14.8% (193) <0.001
Risk factor: HTN 53.8% (1189) 38.3% (357) 65.1% (832) <0.001
Risk factor: HLP 33.6% (708) 23.7% (210) 40.7% (498) <0.001
Diabetes mellitus 15.6% (347) 9.3% (86) 20.1% (261) <0.001
Smoking 34.3% (633) 34.3% (264) 34.3% (369) 1.000
Positive family 
history of CAD
32.4% (477) 32.3% (202) 32.5% (275) 0.956
Grace score <109 69.3% (1413) 86.1% (736) 57.2% (677) <0.001
109–140 21.9% (446) 12.7% (109) 28.5% (337)
>140 8.8% (179) 1.2% (10) 14.3% (169)
Killip class I 96% (2084) 98.4% (900) 94.3% (1184) <0.001
II 3.2% (70) 1.6% (15) 4.4% (55)
III 0.7% (15) 0% (0) 1.2% (15)
IV 0% (1) 0% (0) 0.1% (1)
ECG not diagnostic 87.3% (1971) 93% (892) 83% (1079) <0.001
ST-elevation 4.2% (94) 2.6% (25) 5.4% (69) 0.002
ST-depression 7.7% (170) 3.6% (34) 10.7% (136) <0.001
Local cTn negative 87.9% (2017) 100% (974) 79% (1043) <0.001
Copeptin [pmol/l] 7.0 (3.9, 11.8) 4.9 (3.2, 7.7) 10.2 (5.3, 22.9) <0.001
Copeptin negative 70.4% (1615) 100% (974) 48.6% (641) <0.001
Local troponin and 
copeptin
negative 64.4% (1477) 100% (974) 38.1% (503) <0.001
Numbers are medians, interquartile ranges and p values of Wilcoxon rank-sum test for numerical variables and, percentages, counts and 
p values of X2 test for categorical variables.
CAD, coronary artery disease; cTn, cardiac troponin; HLP, hyperlipidaemia; HTN, hypertension; MI, myocardial infarction. 
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spent longer times in the ED. However, and importantly, 
rates of all-cause mortality at 30 days were not significantly 
different (0.2% vs 0.1%, p=1) compared with the primary 
discharge after fast rule-out pathway.
Outcomes
The primary endpoint, all-cause death within 30 days 
among the primary discharge after fast rule-out pathway, 
occurred in only one case of 974 patients (0.1%, 95% CI: 
0% to 0.6%). This death was not related to the biomarker 
algorithm: the patient was 70 years old, had a history of 
CAD and previous MI and presented with musculoskeletal 
symptoms, was primarily discharged and died 1 month 
later from metastatic lung cancer (table 3).
By contrast, all-cause mortality rate in the conventional 
care pathway was 1.1% (14 of 1320 patients, 95% CI: 
0.6% to 1.8%) and thus significantly higher (p=0.011) 
than in the primary discharge after fast rule-out pathway 
(table 3). Diagnoses in the deceased patients of the 
conventional care pathway included ACS (n=5), non-car-
diac chest pain (n=2), pulmonary disease (n=2), neuro-
logical disease (n=1), rhythm disorders (n=1), stable CAD 
(n=1), heart failure (n=1), gastrointestinal disease (n=1) 
and non-specified others (n=1). Patients who died were a 
median of 15 years older, had more often dyspnoea as the 
leading presenting symptom, presented more frequently 
more than 12 hours after symptom onset and were charac-
terised by higher GRACE score (167 vs 90 points, p<0.001) 
and Killip class. In addition, non-survivors had received 
more extensive diagnostic workup, presented more often 
with a local cTn and Copeptin above cut-off and median 
Copeptin values were significantly higher than among 
survivors (50.8 vs 7.0 pmol/L, p<0.001) underscoring 
the prognostic information that is provided by cTn and 
Copeptin independent of the underlying disease.
Regarding secondary endpoints, hospitalisation rates 
were 0.1% in the primary discharge after fast rule-out 
pathway compared with 59% in the conventional care 
pathways (p<0.001). As expected, median lengths of stay in 
the ED (treatment time) were significantly shorter in the 
primary discharge after fast rule-out pathway versus the 
conventional care pathway (228 min vs 288 min, p<0.001) 
and rates of patients discharged within 0 to <1 hour (1.5% 
vs 3.6%), 1 to <2 hours (13.2% vs 13.3%), 2 to <3 hours 
(21.7% vs 16%), 3 to <6 hours (49.3% vs 37.3%) were 
significantly different in primary discharge after fast 
rule-out pathway versus conventional care pathway (p for 
trend <0.001). Conversely, rates of patients with longer 
ED treatment times >6 hours were significantly lower in 
the primary discharge after fast rule-out pathway than 
in the conventional care pathway out group (14.2% vs 
29.8%, p<0.001).
DIsCussIOn
Information on the safety of direct discharge from an 
ED after rule-out of MI in patients with suspected ACS is 
almost exclusively restricted to findings that were gener-
ated in observational trials where attending physicians 
were commonly blinded to the investigational hs-cTn 
results, or to retrospectively determined optimal decision 
cut-offs. Treatment decisions based on at that time appli-
cable standards of care and were left at the discretion of 
the treating physician.16–19 31
Following the randomised BIC-8 study, which proofed 
safe discharge after instant rule-out of AMI by the use 
of troponin and Copeptin from a single blood draw22 
and also showed cost-effectiveness in a health economic 
substudy,32 we could confirm in a large European registry 
that this is also true in clinical routine.
The superior analytical sensitivity of hs-cTn assays has 
already enabled an accurate rule-out of MI with sensitivi-
ties and NPVs of >90%,10 facilitating fast rule-out based on 
either very low concentrations of hs-cTn assays obtained 
from a single measurement at presentation,14–19 33 or 
from serial blood draws after 1 to 3 hours17–19 31 34–39 using 
hs-cTn at the 99th percentile10–13 or slightly below18 19 the 
99th percentile of a healthy reference population. Inte-
gration of clinical judgement or a validated clinical score 
such as the GRACE, TIMI, HEART, modified Goldman 
Score, MACS clinical decision rule, EDACS and Vancouver 
Chest Pain Algorithm and North American Chest Pain 
Rule further improve NPV yielding NPV between 98.1% 
to 100% and 98.4% to 100% when cTn and hs-cTn assays 
were used, respectively.40 Although, 2015 ESC guidelines10 
discourage routine invasive strategy in low risk patients 
and rather recommend discharge following risk stratifica-
tion, and a pre-discharge or post-discharge stress imaging 
test to decide on a selective invasive strategy, evidence from 
randomised trials to endorse these recommendations is 
Figure 2 Algorithm for an early rule-out strategy and 
guidance of primary early discharge versus general hospital 
admission (conventional workup). ACS, acute coronary 
syndrome. 
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sparse.20–22 The Manchester Acute Coronary Syndrome 
(MACS)-Pilot study20 enrolled 138 patients with suspected 
cardiac chest pain who were randomised to receive care 
guided by the MACS decision rule or standard care. The 
primary efficacy outcome was a decision to discharge 
within 4 hours of arrival, without missed MI and without 
death, AMI or coronary revascularisation occurring 
during 30 days of follow-up. This small pilot study found a 
significantly higher rate of uneventful primary discharge 
within 4 hours (26% vs 8%, p=0.004) among those guided 
by the MACS rule. The HEART Pathway Trial enrolled 282 
patients with suspected ACS stratified into risk categories 
using the HEART Score.21 The study was not powered to 
compare event rates in randomised groups but found a 
decreased objective cardiac testing at 30 days by 12.1%, 
a reduced length of stay by 12 hours and an increase of 
Table 2 Comparison of patient’s characteristics of primary discharge versus over-rule to conventional care despite eligibility 
for discharge by biomarker results





Age 59 (46, 72) 51 (39, 62) 61 (51.5, 73) <0.001
Gender Female 47.2% (697) 49.7% (484) 42.3% (213) 0.009
Onset of symptoms 
before presentation
0–3 hour 24.5% (333) 26% (228) 21.7% (105) 0.060
3–6 hour 12.1% (165) 11.8% (103) 12.8% (62)
6–12 hour 12.1% (164) 13.1% (115) 10.1% (49)
>12 hour 51.3% (698) 49.1% (430) 55.4% (268)
Leading symptom Chest pain 73.9% (1092) 76.9% (749) 68.2% (343) <0.001
Diffuse/initially mixed 
symptoms
10.9% (161) 9.9% (96) 12.9% (65)
Dyspnoea 4.4% (64) 2.5% (24) 8.1% (40)
Abdominal pain 2.8% (41) 3.1% (30) 2.2% (11)
Focal neurology 0.5% (7) 0.4% (4) 0.6% (3)
Headache 0.6% (9) 0.7% (7) 0.4% (2)
Other 6.9% (102) 6.6% (64) 7.6% (38)
History of CAD 24.4% (351) 16.8% (158) 38.9% (193) <0.001
History of MI 9.5% (136) 7.3% (69) 13.5% (67) <0.001
Hypertension 48.7% (693) 38.3% (357) 68.2% (336) <0.001
HLP 29.5% (401) 23.7% (210) 40.6% (191) <0.001
Diabetes mellitus 10.9% (155) 9.3% (86) 13.9% (69) 0.011
Smoking 34.6% (409) 34.3% (264) 35.1% (145) 0.838
Family history CAD 33.6% (322) 32.3% (202) 36% (120) 0.269
Grace score <109 80.7% (1067) 86.1% (736) 70.7% (331) <0.001
109–140 16.8% (222) 12.7% (109) 24.1% (113)
≥140 2.6% (34) 1.2% (10) 5.1% (24)
Killip class I 98.4% (1378) 98.4% (900) 98.4% (478) 0.375
II 1.6% (22) 1.6% (15) 1.4% (7)
III 0.1% (1) 0% (0) 0.2% (1)
Final diagnoses ACS total 6.5% (95) 0.9% (9) 17.1% (86) <0.001
unclassified ACS 1.9% (28) 0.4% (4) 4.8% (24)
UAP 4% (58) 0.4% (4) 10.8% (54)
NSTEMI 0.3% (5) 0.1% (1) 0.8% (4)
AMI other 0.1% (2) 0% (0) 0.4% (2)
STEMI 0.1% (2) 0% (0) 0.4% (2)
Main diagnosis Cardiac 34.4% (503) 23.5% (226) 55.2% (277) <0.001
Mortality 30 days 0.1% (2) 0.1% (1) 0.2% (1) 1
Numbers are medians, IQRs and p values of Wilcoxon rank-sum test for numerical variables and percentages, counts and p values of 
X2 test for categorical variables.ACS, acute coronary syndrome; AMI, acute myocardial infarction; CAD, coronary artery disease; HLP, 
hyperlipidaemia; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation 
myocardial infarction; UAP, unstable angina pectoris. 
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early discharges by 21.3%. The BIC-8 trial22 that enrolled 
a total of 902 low-to-intermediate high risk patients using 
the GRACE score and subsequently randomised patients 
with normal presenting cTn and Copeptin values into an 
early discharge and a standard protocol group. The study 
demonstrated a reduction of observation time in the ED 
by more than 40% from a median of 7 hours to 3 hours, 
achieved a 5.6-fold increase in ED discharge rate from 
67.7% versus 12%, and a similar 5.2% rate of 30 day major 
adverse cardiovascular events that were liberally defined 
as all-cause death, survived sudden cardiac arrest, re-hos-
pitalisation for ACS, unplanned PCI or CABG or docu-
mented life-threatening arrhythmias in the standard and 
Copeptin group.22
The present large multicenter registry was performed 
in patients with suspected ACS and low-to-intermediate 
risk to test the usefulness of a dual biomarker strategy, 
consisting of a normal Copeptin and cTn, to rule-out MI 
from a single blood draw at admission and to discharge 
low risk patients primarily from the ED. In order to repre-
sent clinical practice of different type of institutions, vari-
able local practice and across the spectrum of cTn assays 
and grades of assays sensitivities,41 42 this observational 
study was conducted in 18 different institutions in Europe 
and Asia. Institutions included EDs in community hospi-
tals, and CPUs in PCI centres and few university hospi-
tals. Patients qualified for enrolment in the presence of 
a broader spectrum of symptoms suggestive of ACS not 
limited to chest pain or angina, and a broad spectrum 
of cTn assays and different grades of analytical sensitiv-
ities including conventional, contemporary and hs-cTn 
assays was permitted. To reduce dominance of few high 
recruiting centres, enrolment rates were restricted to 300 
study patients per site.
There were several key findings of this survey that 
support the usefulness and safety of this concept in clin-
ical routine and outside of controlled clinical trials. First, 
earlier discharge from the ED in patients ruled-out at 
presentation using a single blood draw is feasible without 
any obvious safety concern. All-cause mortality rate within 
30 days was 0.1% and attributed to a case with metastatic 
lung cancer. Second, length of stay in the ED is signifi-
cantly shorter by 60 min allowing an earlier discharge, 
a finding particularly useful in congested EDs or CPUs. 
Thus, the present registry data confirm the findings from 
the randomised BIC-8 trial22 on reduced length of stay, 
increased discharge rates and support the safety of a 
primary planned discharge from an ED after clinical risk 
assessment. Third, the dual marker concept is efficient 
as it can be applied to at least 42.5% (potentially effec-
tive in 66.4%) of patients presenting with chest pain or 
chest pain equivalent symptoms to an ED. Thus, efficacy 
of this dual marker strategy is almost comparable with the 
efficacy of the ESC recommended 0/1 hour diagnostic 
algorithm that requires serial blood draws and a validated 
hs-cTn assay (currently Abbott Architect hs-cTnI and 
Roche hs-cTnT). While other fast rule-out algorithms 
based on very low hs-cTnI or hs-cTnT at the limit of 
blank or limit of detection may demonstrate similar diag-
nostic performance and safety, the numbers of patients 
who qualify are substantially lower14 15 33 and these strat-
egies have never been tested prospectively with patients 
being really discharged after testing.
Table 3 All-cause death at 30 days and secondary outcomes
Variable Categories Total (2294 patients)
Primary discharge 
after fast rule out (974 
patients)
Conventional work up 
(1320 patients)
All-cause death 30 days 0.7% (0.4%–1.1%) 
n=15
0.1% (0%–0.6%), n=1* 1.1% (0.6%–1.8%) n=14
Exact length of stay in 
ED/CPU (hours)
4.3 (4.1–4.5) 3.8 (3.6–4.0) 4.8 (4.7–5.0)
Length of stay in ED/
CPU
0–1 hour 2.6% (n=53) 1.5% (n=13) 3.6% (n=40)
1–2 hour 13.3% (n=266) 13.2% (n=118) 13.3% (n=148)
2–3 hour 18.6% (n=372) 21.7% (n=194) 16% (n=178)
3–6 hour 42.7% (n=855) 49.3% (n=440) 37.3% (n=415)
>=6 hour 22.9% (n=458) 14.2% (n=127) 29.8% (n=331)
Admission Peripheral ward 72.7% (n=562) 100% (n=1) 72.7% (n=561)
IMCU 17.6% (n=136) 0% (n=0) 17.6% (n=136)
ICU 9.7% (n=75) 0% (n=0) 9.7% (n=75)
Percentages and counts (denoted by ‘n=’) for categorical variables and medians for the numeric variable ‘Exact length of stay in ED/CPU’; 
95% CIs added in brackets for all-cause death and exact length of stay in ED/CPU.
*70 years old male, known CAD, MI and cold/asthma, Tn and Copeptin negative, ECG normal, diagnosis: non-cardiac, atypical chest pain 
(musculoskeletal), death 1 month later from metastatic lung cancer.
CAD, coronary artery disease; CPU, chest pain unit; ED, emergency department; ICU, intensive care unit; IMCU, intermediate care unit; MI, 
myocardial infarction; Tn, troponin. 
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We found a relevant number of over-rule by local ED 
physician leading to an admission of patients who qual-
ified for discharge by their biomarker results (34%). 
Given that these patients had an uneventful clinical 
course (see table 2), void of primary or secondary events 
during follow-up, suggests an underestimated efficacy 
and more potential of safe discharge. Fourth, regarding 
the diagnostic performance for rule-out that was not 
in the scope of this survey, the dual marker algorithm 
was associated with a high negative predictive value of 
99.9% for NSTEMI (one missed NSTEMI) confirming 
the existing evidence on the diagnostic performance of 
the Copeptin/troponin dual marker strategy.22 26–28 Fifth, 
regarding secondary objectives, the dual marker strategy 
was associated with shorter stays in ED. Sixth, consistently 
with previous studies,26–28 43 44 elevated Copeptin levels 
were associated with all-cause mortality within 30 days 
providing confirmatory evidence that Copeptin confers 
prognostic information that is complementary to cTn or 
hs-cTn, in various acute cardiovascular settings including 
ACS,26–28 43 44 heart failure45 46 and acute pulmonary 
embolism47 but also non-cardiac disease. In addition, an 
elevated Copeptin should prompt a search for a variety 
of potentially life-threatening non-cardiac conditions 
including perforated stomach ulcer, pancreatitis, chole-
cystitis, bleedings, infections or neurological disorders.48
limitations
First, we observed very low rates of all-cause mortality at 
30 days, that is, 0.1% (95% CI: 0% to 0.6%) in the primary 
discharge after fast rule-out pathway as compared with 
1.1% (95% CI: 0.6% to 1.8%) in the conventional care 
pathway. Low event rates may be explained by restriction 
of the DMS algorithm to patients at low or intermediate 
risk based on the GRACE score. Therefore, our findings 
cannot be extrapolated to settings where risk stratification 
after rule-out is based on other clinical scores or on clin-
ical judgement. Moreover, a selection bias towards recruit-
ment of a non-representable low risk ACS cohort cannot 
be fully excluded as inclusion criteria were not limited to 
typical chest pain, longer pain episodes or abnormal ECG 
findings. However, the study population was planned to 
represent a real life picture of patients who present in 
clinical routine with various symptoms and a wide range 
of risk. Copeptin concentration return to normal within 
few hours reducing the diagnostic performance of the 
DMS algorithm to early presenters. As a tribute to the 
consecutive enrolment of patients, we were not able to 
enrich the study population by patients presenting within 
6 hours from onset of symptoms (49.2% of the entire 
study cohort reported onset of symptoms more than 
12 hours before presentation). Therefore, scrutiny is 
advised regarding the interpretation of the DMS result in 
patients presenting very late or who cannot state a precise 
onset of symptoms. We believe that our study cohort is 
also similar to other observational studies enrolling 
patients with suspected ACS. The overall prevalence of 
ACS in this registry was 12.7% and is thus very consistent 
with a median of 13% to 14% prevalence of ACS reported 
in a pooled analysis of 51 observational trials on patients 
with suspected ACS.2 In addition, the median GRACE 
score was 89 points (IQR: 67 to 114) which is very similar 
with the mean GRACE score of 80 (SD 28 points) in the 
randomised intervention trial.22
Second, rates of enrolment per site were heteroge-
neous with a mix of high and low recruiting centres. 
However, the very low mortality rate does not allow any 
exploratory analyses on the safety of discharge by centre 
volumes, experience of physicians, local cTn assay or 
assay generation.
Third, currently a strategy for instant rule-out based on 
Copeptin and cTn is being recommended by 2015 ESC 
guidelines on NSTE-ACS10 and an updated consensus 
document of the German Society of Cardiology on the use 
of Copeptin in CPUs49 and chest pain centres.50 However, 
there is a gap between the high recommendation level 
endorsed by numerous clinical trials,23–26 43 44 editorials 
and state-of-the-art reviews,38 40 meta-analysesp27 28 and 
national practice guidelines10 49 50 on the one hand and 
the obvious underuse in clinical practice for suspected 
ACS. In the elective setting, Copeptin is currently used 
for the diagnosis of diabetes insipidus, a non-emergent 
diagnosis. In emergencies requiring immediate measure-
ment, the most probable reason for underuse is that 
Copeptin has to be measured on a stand-alone device 
that is more labour-intensive than an automated central 
laboratory system, which leads to the suspicion that nowa-
days economic features in the laboratory are hurdles 
for state of the art use of biomarkers. Development of 
a POCT system for Copeptin and implementation of 
Copeptin to a central laboratory platform would over-
come this obstacle. In this registry, however, Copeptin was 
measured on a Kryptor platform with a measuring time of 
14 min and immediate reporting of the result to the ED 
physician. Accordingly, most of the time delays between 
diagnosis and the disproportionally longer stay in ED are 
regarded to be related to other time consuming processes 
including diagnostic workup for differential diagnoses 
and drafting of the discharge report, particularly in the 
presence of crowding in the ED.
COnClusIOns
Copeptin on top of cardiac troponin is currently the 
only strategy that – based on a randomised control trial 
and a large multicentre registry - supports the safe direct 
discharge of patients with chest pain or chest pain equiv-
alent symptoms suggestive of ACS under routine condi-
tions. There are only few randomised trials that provide 
evidence for a safe discharge after rule-out in low risk 
patients. The present registry confirms findings from 
the randomised BIC-8 trial in an independent real world 
registry. The efficacy of the DMS in terms of patients 
potentially qualifying is at least 42.5% or potentially 
considerably higher.
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We believe that the present findings have potential 
impact on healthcare resources by shortening obser-
vation times, hospitalisation rates, reducing diagnostic 
resources and avoid unnecessary coronary angiographies 
should barriers to adoption be overcome.
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